Gamma index comparison has been established as a method for patient specific quality assurance in IMRT. Detector arrays can replace radiographic film systems to record 2D dose distributions and fulfill quality assurance requirements. These electronic devices present spatial resolution disadvantages with respect to films. This handicap can be partially overcome with a multiple acquisition sequence of adjacent 2D dose distributions. The detector spatial response influence can also be taken into account through the convolution of the calculated dose with the detector spatial response. A methodology that employs both approaches could allow for enhancements of the quality assurance procedure. 35 beams from different step and shoot IMRT plans were delivered on a phantom. 2D dose distributions were recorded with a PTW-729 ion chamber array for individual beams, following the multiple acquisition methodology. 2D dose distributions were also recorded on radiographic films. Measured dose distributions with films and with the PTW-729 array were processed with the software RITv5.2 for Gamma index comparison with calculated doses. Calculated dose was also convolved with the ion chamber 2D response and the Gamma index comparisons with the 2D dose distribution measured with the PTW-729 array was repeated. 3.7 ± 2.7% of points surpassed the accepted Gamma index when using radiographic films compared with calculated dose, with a minimum of 0.67 and a maximum of 13.27. With the PTW-729 multiple acquisition methodology compared with calculated dose, 4.1 ± 1.3% of points surpassed the accepted Gamma index, with a minimum of 1.44 and a maximum of 11.26. With the PTW- multiple acquisition methodology compared with convolved calculated dose, 2.7 ± 1.3% of points surpassed the accepted Gamma index, with a minimum of 0.42 and a maximum of 5.75. The results obtained in this work suggest that the comparison of merged adjacent dose distributions with convolved calculated dose represents an enhancement in the methodology for IMRT patient specific quality assurance with the PTW-729 ion chamber array.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13246-016-0498-y | DOI Listing |
Vaccines (Basel)
December 2024
Center for Advanced Technologies, Tashkent 100174, Uzbekistan.
The development of effective and safe vaccines and their timely delivery to the public play a crucial role in preventing and managing infectious diseases. Many vaccines have been produced and distributed globally to prevent COVID-19 infection. However, establishing effective vaccine development platforms and evaluating their safety and immunogenicity remains critical to increasing health security, especially in developing countries.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
National Institutes for Food and Drug Control, No. 31, Huatuo Road, Beijing 102629, China.
Background: The Vero cell rabies vaccine is currently the most widely used human rabies vaccine. However, owing to the presence of residual host cell DNA (HCD) in the final product and the potential tumorigenicity of the DNA of high-passage Vero cells, the WHO not only sets a limit on the number of times cells used in production can be passaged, but also imposes strict requirements on the amount of residual HCD in the final vaccine product.
Objectives: To systematically reduce the HCD level in the final vaccine product, multiple purification steps are included in the vaccine production process.
Pharmaceutics
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
: Community-acquired methicillin-resistant (CA-MRSA) greatly complicates the treatment of skin and soft tissue infections (SSTI). It was previously found that subcutaneous (SQ) treatment with the mononuclear phagocyte (MP)-selective activator complements peptide-derived immunostimulant-02 (CPDI-02; formerly EP67) and increases prophylaxis of outbred CD-1 mice against SQ infection with CA-MRSA. Here, we determined if treatment with CPDI-02 also increases curative protection.
View Article and Find Full Text PDFPharmaceutics
December 2024
Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hiro-koshingai, Kure 737-0112, Japan.
Background: 5-Aminosalicylic acid (5-ASA), the first-line therapy for ulcerative colitis, is a poorly soluble zwitterionic drug. Unformulated 5-ASA is thought to be extensively absorbed in the small intestine.
Methods: The pH-dependent solubility of 5-ASA in vitro and the intestinal membrane distribution of 5-ASA and its N-acetyl metabolite (AC-5-ASA) after the oral administration of 5-ASA were examined in fed rats.
Pharmaceutics
December 2024
Department of Psychiatry, Oxford University, Warneford Hospital, Oxford OX3 7JX, UK.
: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders. However, it has poor oral bioavailability. We investigated the effect of a novel lipid formulation on its absorption in humans and on its tissue distribution in mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!